| Abstract | OBJECTIVE: The efficacy of ertapenem, 1 g once a day, for treatment of adults with serious infections caused by Enterobacteriaceae was compared with ceftriaxone 1 g once a day [complicated urinary tract infection (CUTI) and community-acquired pneumonia (CAP)] or piperacillin-tazobactam, 3.375 g every 6 h (complicated intra-abdominal, complicated skin/skin structure and acute pelvic infections). PATIENTS AND METHODS: This combined analysis included the subgroup of all 1167 treated patients infected with Enterobacteriaceae from seven randomized double-blind studies. RESULTS: Escherichia coli was the most common pathogen, accounting for 65.3% of all Enterobacteriaceae. Among evaluable patients with deep tissue (intra-abdominal, skin and pelvic) infections, the combined clinical cure rates were 84.8% (223 of 263) for ertapenem and 82.9% (194 of 234) for piperacillin-tazobactam [95% confidence interval (CI) for the difference, adjusting for infection, -4.9% to 8.9%]. Cure rates by infection for ertapenem and piperacillin-tazobactam, respectively, were: intra-abdominal, 85.1% (143 of 168) and 79.9% (119 of 149); pelvic, 86.8% (46 of 53) and 94% (47 of 50); skin/skin structure, 81% (34 of 42) and 80% (28 of 35). Among patients with CUTI, microbiological cure rates were 90.5% (220 of 243) for ertapenem and 92% (196 of 213) for ceftriaxone (95% CI for the difference, -7.1% to 4.1%). In patients with CAP, clinical cure rates were 95% (19 of 20) for ertapenem and 88.9% (16 of 18) for ceftriaxone. CONCLUSION: Ertapenem therapy was as effective as either piperacillin-tazobactam or ceftriaxone for serious infections caused by Enterobacteriaceae. |
| Authors | Richard M Gesser, Kathleen McCarroll, Hedy Teppler, Gail L Woods
(Affiliation: Merck Research Laboratories, West Point, PA 19486-0004, USA.)
|
| Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 51
Issue 5
Pg. 1253-60
(May 2003)
ISSN: 0305-7453 England |
| PMID | 12697633
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Cephalosporins
- Lactams
- beta-Lactams
- ertapenem
- Piperacillin
- Ceftriaxone
- Penicillanic Acid
- tazobactam
|
| Topics |
- Adult
- Aged
- Ceftriaxone
(therapeutic use)
- Cephalosporins
(therapeutic use)
- Community-Acquired Infections
(drug therapy, microbiology)
- Double-Blind Method
- Drug Therapy, Combination
- Enterobacteriaceae Infections
(drug therapy, microbiology)
- Escherichia coli Infections
(drug therapy, microbiology)
- Humans
- Lactams
(therapeutic use)
- Middle Aged
- Multicenter Studies as Topic
- Penicillanic Acid
(analogs & derivatives, therapeutic use)
- Piperacillin
(therapeutic use)
- Treatment Outcome
- Urinary Tract Infections
(drug therapy, microbiology)
- beta-Lactams
|
